<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-17-03-2026-shutterstock_2556717557-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-17-03-2026-shutterstock_2556717557-430x241.jpg"/></p>
<p>該項目正在完成 IIA 期臨牀試驗，預計在 2026 年上半年結束前公佈數據。圖片來源：Gorodenkoff / Shutterstock.com。</p>
<p>Zydus Lifesciences 的子公司 Sentynl Therapeutics 已與韓國公司 PRG S&amp;T 簽署協議，獲得 Progerinin（SLC-D011）的許可，這是一種用於治療哈欽森 - 吉爾福德早衰綜合症（HGPS）的研究分子。</p>
<p>此舉使 Sentynl 能夠立即與 PRG S&amp;T 合作，推進該分子的臨牀開發，該分子已獲得美國食品藥品監督管理局（FDA）的孤兒藥資格。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - Donaperminogene Seltoplasmid 在肌萎縮側索硬化症中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - PR-006 在額顳葉痴呆（FTD）中的應用</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>Sentynl 將獲得 Progerinin 的全部權利，前提是達到某些里程碑。該項目目前正在完成 IIA 期臨牀試驗，預計在 2026 年上半年結束前公佈數據。</p>
<p>一旦完成，該療法將成為 Sentynl 針對 HGPS 的第二個產品。</p>
<p>Progerinin 是一種口服活性小分子藥物，正在開發用於治療 HGPS，這是一種由 LMNA 基因突變引起的罕見疾病，導致 progerin 積累和細胞過早老化。</p>
<p>該藥物旨在抑制 progerin 在細胞內的影響，可能改善細胞核的完整性並減少損傷。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報</p>
<p>Progerinin 目前尚未獲得任何衞生機構的批准。早期研究和臨牀試驗旨在評估其是否能夠減緩 HGPS 患者的疾病進展並改善生存率。</p>
<p>Zydus Lifesciences 的董事總經理 Dr Sharvil Patel 表示：“此次收購標誌着我們在擴大哈欽森 - 吉爾福德早衰綜合症治療組合方面的重要一步，如果不加以治療，該病可能對患者健康產生嚴重影響。</p>
<p>“支持患者過上健康、充實的生活是我們工作的核心，與 PRG S&amp;T 的協議直接推動了這一使命，通過推進孤兒藥物治療影響罕見疾病的患者和家庭。”</p>
<p>Sentynl 首席執行官 Matt Heck 表示：“患有哈欽森 - 吉爾福德早衰綜合症的兒童面臨着無情的疾病。然而，我們在早衰研究中看到了真正的進展，新科學正在改變可能性。</p>
<p>“這項協議將 Progerinin 納入我們的早衰產品組合，代表了我們將這一進展轉化為另一個真正療法的承諾，以幫助需要它的兒童和家庭。”</p>
<p>在 2024 年 5 月，Sentynl 宣佈全球收購 Eiger BioPharmaceuticals 的 Zokinvy（lonafarnib）項目，用於治療早衰。</p>

醫藥突破 ETF - ALPS

ZYXIQ

生物科技 ETF - VanEck Vectors

<p>Sentynl Therapeutics 已與 PRG S&T 達成合作，獲得了用於治療哈欽森 - 吉爾福德早衰綜合症（HGPS）的實驗性藥物 Progerinin 的許可。該藥物目前正在進行 IIA 期臨牀試驗，預計將在 2026 年中期公佈結果。Sentynl 將在達到特定里程碑後獲得 Progerinin 的完全權利。這項協議增強了 Sentynl 針對罕見疾病的產品組合，體現了他們改善 HGPS 患者生活的承諾</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-17-03-2026-shutterstock_2556717557-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-17-03-2026-shutterstock_2556717557-430x241.jpg"/></p>
<p>The programme is completing a Phase IIA trial, with data expected before the end of H1 2026. Credit: Gorodenkoff / Shutterstock.com.</p>
<div class="lb-trans"><p>該項目正在完成 IIA 期臨牀試驗，預計在 2026 年上半年結束前公佈數據。圖片來源：Gorodenkoff / Shutterstock.com。</p>
</div><p>Zydus Lifesciences subsidiary Sentynl Therapeutics has signed an agreement with Korean company PRG S&amp;T to license Progerinin (SLC-D011), an investigational molecule intended to treat Hutchinson-Gilford Progeria Syndrome (HGPS).</p>
<div class="lb-trans"><p>Zydus Lifesciences 的子公司 Sentynl Therapeutics 已與韓國公司 PRG S&amp;T 簽署協議，獲得 Progerinin（SLC-D011）的許可，這是一種用於治療哈欽森 - 吉爾福德早衰綜合症（HGPS）的研究分子。</p>
</div><p>The move enables Sentynl to collaborate immediately with PRG S&amp;T to advance clinical development of the molecule, which holds orphan drug status from the US Food and Drug Administration (FDA).</p>
<div class="lb-trans"><p>此舉使 Sentynl 能夠立即與 PRG S&amp;T 合作，推進該分子的臨牀開發，該分子已獲得美國食品藥品監督管理局（FDA）的孤兒藥資格。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Donaperminogene Seltoplasmid in Amyotrophic La...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Donaperminogene Seltoplasmid 在肌萎縮側索硬化症中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - PR-006 in Frontotemporal Dementia (FTD)</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - PR-006 在額顳葉痴呆（FTD）中的應用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Sentynl will acquire full rights to Progerinin, provided certain milestones are achieved. The programme is presently completing a Phase IIA clinical trial, with data anticipated before the end of the first half of 2026.</p>
<div class="lb-trans"><p>Sentynl 將獲得 Progerinin 的全部權利，前提是達到某些里程碑。該項目目前正在完成 IIA 期臨牀試驗，預計在 2026 年上半年結束前公佈數據。</p>
</div><p>Upon closing, this therapy would become Sentynl’s second offering aimed at treating HGPS.</p>
<div class="lb-trans"><p>一旦完成，該療法將成為 Sentynl 針對 HGPS 的第二個產品。</p>
</div><p>Progerinin is an orally active small-molecule drug, which is being developed as a treatment for HGPS, a rare condition caused by mutations in the LMNA gene resulting in progerin accumulation and premature cellular ageing.</p>
<div class="lb-trans"><p>Progerinin 是一種口服活性小分子藥物，正在開發用於治療 HGPS，這是一種由 LMNA 基因突變引起的罕見疾病，導致 progerin 積累和細胞過早老化。</p>
</div><p>The drug aims to inhibit progerin’s effects within cells, potentially improving nuclear integrity and reducing damage.</p>
<div class="lb-trans"><p>該藥物旨在抑制 progerin 在細胞內的影響，可能改善細胞核的完整性並減少損傷。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>Progerinin is not currently approved by any health authority. Early research and clinical studies are designed to assess whether it can slow disease progression and improve survival in HGPS patients.</p>
<div class="lb-trans"><p>Progerinin 目前尚未獲得任何衞生機構的批准。早期研究和臨牀試驗旨在評估其是否能夠減緩 HGPS 患者的疾病進展並改善生存率。</p>
</div><p>Zydus Lifesciences managing director Dr Sharvil Patel said: “This acquisition marks an important step in growing our portfolio of therapies for Hutchinson-Gilford Progeria Syndrome, which can have severe impacts on patient health if left untreated.</p>
<div class="lb-trans"><p>Zydus Lifesciences 的董事總經理 Dr Sharvil Patel 表示：“此次收購標誌着我們在擴大哈欽森 - 吉爾福德早衰綜合症治療組合方面的重要一步，如果不加以治療，該病可能對患者健康產生嚴重影響。</p>
</div><p>“Supporting patients in living healthy, fulfilled lives is core to what we do, and the agreement with PRG S&amp;T directly furthers this mission by advancing orphan therapies for patients and families impacted by rare diseases.”</p>
<div class="lb-trans"><p>“支持患者過上健康、充實的生活是我們工作的核心，與 PRG S&amp;T 的協議直接推動了這一使命，通過推進孤兒藥物治療影響罕見疾病的患者和家庭。”</p>
</div><p>Sentynl CEO Matt Heck said: “Children with Hutchinson-Gilford Progeria Syndrome face an unforgiving disease. However, we are seeing real progress in progeria research, with new science changing what’s possible.</p>
<div class="lb-trans"><p>Sentynl 首席執行官 Matt Heck 表示：“患有哈欽森 - 吉爾福德早衰綜合症的兒童面臨着無情的疾病。然而，我們在早衰研究中看到了真正的進展，新科學正在改變可能性。</p>
</div><p>“This agreement, which will add Progerinin to our progeria portfolio, represents our commitment to translating that progress into another real therapy for children and families who need them.”</p>
<div class="lb-trans"><p>“這項協議將 Progerinin 納入我們的早衰產品組合，代表了我們將這一進展轉化為另一個真正療法的承諾，以幫助需要它的兒童和家庭。”</p>
</div><p>In May 2024, Sentynl announced the worldwide acquisition of the Zokinvy (lonafarnib) programme from Eiger BioPharmaceuticals for the treatment of progeria.</p>
<div class="lb-trans"><p>在 2024 年 5 月，Sentynl 宣佈全球收購 Eiger BioPharmaceuticals 的 Zokinvy（lonafarnib）項目，用於治療早衰。</p>
</div>

Sentynl 與 PRG 合作獲得 Progerinin 的許可